Health · Pharma & Biotech · 2 hrs ago
Pilot trial tests support to limit weight regain after GLP-1 drugs stop
GLP-1 medicines can help people lose weight, but weight often returns after treatment stops.
People may stop taking them because of cost, insurance limits, side effects or personal preference.
A remote pilot trial tested two kinds of support for the first four months after treatment ended.
It enrolled 39 adults who had lost more than 10% of their body weight on the drugs and stopped less than 30 days earlier.
Participants were assigned to home-delivered meals, a wellness app or usual care.
Researchers mainly assessed whether people used the support and how satisfied they were; changes in weight were an exploratory measure.
The study was small, and the supplied findings do not state whether either option slowed weight regain.
A pilot randomized trial tested whether meals or a digital wellness app could help limit weight regain after people stopped GLP-1 drugs.
The four-month trial compared medically tailored meals, the Noom app and usual care.
The study assigned 39 participants to the three groups, and 34 completed a final weigh-in.
Researchers focused mainly on adherence and satisfaction; changes in weight were exploratory.
- Who
- Researchers and 39 adults who had lost more than 10% of their body weight while taking GLP-1 drugs.
- What
- A pilot trial compared medically tailored meals and a digital wellness app with usual care after participants stopped treatment.
- When
- The trial ran from March 2024 to August 2025.
- Where
- It was conducted remotely, recruiting through obesity clinics in Texas and the StudyFinder platform.
- Why
- Researchers tested practical support options to help slow early weight regain after GLP-1 treatment ends.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
The remote pilot trial began.
The trial period ended.
News-Medical published its report on the study.
- Total assigned
- 39 participants
- Meals group
- 13 participants
- App group
- 12 participants
- Usual-care group
- 14 participants
- Final weigh-in
- 34 participants completed one
- Intervention period
- Four months
Sources
Related news
Dong-A launches three ibuprofen-based cold medicines
Experimental injection reduced visceral fat by 12% in early trials
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
AstraZeneca blames trial design for failed bone disease drug study
Spain withdraws five erectile dysfunction supplements containing undeclared drugs
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
